iRhythm Presents New Data on Ambulatory Cardiac Monitoring
iRhythm Technologies announced new data from the AVALON study, a large real-world retrospective analysis, presented at HRS 2025. This study, evaluating 428,707 commercially insured patients, demonstrated that iRhythm's Zio long-term continuous monitoring (LTCM) service was associated with a higher diagnostic yield, lower likelihood of repeat testing, and reduced cardiovascular events compared to other ambulatory cardiac monitoring products. Additionally, data showed that the MyZio App improved patient engagement and symptom reporting.
iRhythm Technologies (NASDAQ:IRTC) Trading Down 6.2% After Analyst Downgrade
iRhythm Technologies (NASDAQ:IRTC) saw its shares drop 6.2% after Canaccord Genuity lowered its price target from $212 to $198, despite maintaining a "buy" rating. This decline occurred even though the company reported a strong Q4 beat with record revenue of $208.9M and EPS of $0.29, significantly exceeding expectations. Analysts' price target adjustments and insider selling have created near-term selling pressure, though the consensus remains a "Moderate Buy" with an average target of $211.62.
William Blair Maintains Buy on IRTC iRhythm Technologies Feb 2026
William Blair has maintained its "Buy" rating on iRhythm Technologies (IRTC) following a subpoena-related weakness, viewing it as a buying opportunity. The firm did not issue a new price target, leaving investors to rely on previous targets. Meyka AI independently rates IRTC with a B+ grade, considering various financial and market factors.
Canaccord Genuity Group Lowers iRhythm Technologies (NASDAQ:IRTC) Price Target to $198.00
Canaccord Genuity Group has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $198.00 from $212.00, while maintaining a "buy" rating. This adjustment comes despite iRhythm Technologies beating Q4 earnings expectations with revenues of $208.9 million and EPS of $0.29, attributing growth to improved adjusted EBITDA and its first quarter of positive GAAP net income. However, the stock saw a 5.1% decline, trading below its 50- and 200-day averages, alongside a high debt-to-equity ratio and recent insider sales, contributing to near-term valuation and sentiment challenges.
iRhythm Technologies (NASDAQ:IRTC) Given New $215.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $215.00 from $240.00, while maintaining an "overweight" rating. This adjustment comes despite iRhythm beating Q4 earnings expectations with revenue of $208.9 million and EPS of $0.29, compared to a $0.02 consensus. The stock traded down about 5.1% to $150.76 and faces headwinds including a high debt-to-equity ratio and trading below key moving averages, though other analysts have recently issued more optimistic price objectives.
Wells Fargo Maintains iRhythm Holdings (IRTC) Rating, Lowers Price Target
Wells Fargo analyst Nathan Treybeck has maintained an "Overweight" rating for iRhythm Holdings (IRTC) but reduced the price target from $225.00 to $200.00. This adjustment comes amidst varying analyst perspectives on the company, although the average target price from 14 analysts suggests a potential upside of 44.13% from the current price. iRhythm Holdings specializes in digital healthcare, offering device-based technology for ambulatory cardiac monitoring.
Robert W. Baird Lowers iRhythm Technologies (NASDAQ:IRTC) Price Target to $200.00
Robert W. Baird has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) from $220.00 to $200.00, while maintaining an "outperform" rating, suggesting a potential upside of 36.14%. Despite the price target cut, and a 7.5% share drop, iRhythm exceeded quarterly earnings expectations with an EPS of $0.29 (vs. $0.02 expected) and revenue of $208.9M, a 27.1% year-over-year increase. The company remains unprofitable with a negative net margin and P/E ratio, and recent insider sales have occurred.
Truist cuts iRhythm Technologies stock price target on valuation
Truist Securities has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $200 from $215, while maintaining a Buy rating. This adjustment comes despite the company's strong fourth-quarter revenue performance and positive GAAP net income, reflecting a valuation correction due to lower group multiples. iRhythm's innovative products and strategic growth targets suggest continued market adoption, with its MCT product on track for 2027 and a projected $1 billion in revenue and 15% EBITDA margin by the same year.
Canaccord Genuity lowers iRhythm stock price target on valuation
Canaccord Genuity has reduced its price target for iRhythm Technologies (NASDAQ:IRTC) to $198 from $212, while maintaining a Buy rating on the stock due to valuation concerns. Despite the target reduction, iRhythm reported strong fourth-quarter revenue and adjusted EBITDA, exceeding expectations. The company also provided a positive outlook for 2026, though recent Medicare Advantage changes have impacted its stock.
iRhythm stock gains on Street-beating Q4, upcoming growth drivers
iRhythm (Nasdaq: IRTC) shares rose after a strong fourth quarter in 2025, beating Wall Street expectations for both profits and sales. The company reported its first-ever positive quarterly GAAP net income, driven by increased demand for its Zio long-term continuous monitoring services. Analysts maintain a "Buy" rating, citing upcoming growth drivers like the Zio AT platform and the anticipated launch of the next-generation Zio MCT.
iRhythm Tech earnings beat by $0.16, revenue topped estimates
iRhythm Tech (NASDAQ: IRTC) exceeded analyst expectations for its fiscal fourth quarter, reporting an EPS of $0.17 against an estimated $0.01, and revenue of $208.9M, surpassing the consensus of $201.08M. The company also provided strong Q1 2026 revenue guidance, projecting between $870.00M and $880.00M, above analyst estimates. Despite recent stock fluctuations, iRhythm Tech maintains a "good performance" financial health rating according to InvestingPro.
iRhythm Tech earnings beat by $0.16, revenue topped estimates
iRhythm Technologies (NASDAQ: IRTC) exceeded analyst expectations for its fourth-quarter earnings and revenue. The company reported an EPS of $0.17, significantly higher than the estimated $0.01, and revenue of $208.9 million, surpassing the consensus of $201.08 million. iRhythm Tech also provided an optimistic revenue guidance for Q1 2026.
iRhythm Holdings, Inc. SEC 10-K Report
iRhythm Holdings, Inc. has released its annual 10-K report, showcasing significant financial growth with a 26% revenue increase to $747.1 million and a substantial reduction in net loss to $(44.6) million in 2025. The company detailed its strategic initiatives, including new product launches and partnerships to expand into adjacent clinical areas, while also outlining challenges such as regulatory, market, and operational risks stemming from its reliance on Medicare reimbursements and intense market competition. Despite these risks, iRhythm maintains a strong financial position and plans for continued growth and product development.
iRhythm Technologies Q4 Earnings Call Highlights
iRhythm Technologies reported a "breakout year" in 2025, achieving its first positive quarterly net income and full year of positive adjusted EBITDA and free cash flow. The company saw strong volume growth, particularly from primary care and EHR integrations, and highlighted progress in AI pilots with high accuracy rates. Looking ahead to 2026, iRhythm anticipates continued revenue growth and margin improvement, while also addressing regulatory scrutiny and targeting a H1 2027 launch for its next-generation MCT device.
iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
iRhythm Holdings, Inc. announced its financial results for the fourth quarter and full year 2025, reporting significant revenue growth and profitability milestones. The company achieved a record revenue of $208.9 million in Q4 2025, a 27.1% increase, and registered its first quarter of positive GAAP net income. For the full year, revenue reached $747.1 million, a 26.2% increase, and the company expects continued growth in 2026 with projected revenues of $870 million to $880 million.
iRhythm Technologies (NASDAQ:IRTC) Issues Quarterly Earnings Results
iRhythm Technologies (NASDAQ:IRTC) reported its quarterly earnings, announcing an EPS of $0.29, significantly beating analysts' estimates of $0.02. Despite the positive EPS surprise, the company remains unprofitable with negative ROE and net margin. Following the announcement, IRTC shares rose by $5.03 to $158.88 on above-average volume, and several analysts increased their price targets, contributing to a "Moderate Buy" consensus rating.
Earnings To Watch: iRhythm (IRTC) Reports Q4 Results Tomorrow
iRhythm Technologies (IRTC) is set to report its Q4 results this Thursday after market close. Analysts expect revenue growth of 22.9% year-on-year to $202 million and adjusted earnings of $0.06 per share. The company has a strong history of beating revenue estimates, and its stock is currently trading below the average analyst price target.
Behavioral Patterns of IRTC and Institutional Flows
This article analyzes behavioral patterns and institutional flows for iRhythm Technologies Inc. (NASDAQ: IRTC), highlighting positive near-term sentiment within a long-term strength context despite mid-term weakness. It provides critical support and resistance signals, outlines three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging), and includes a multi-timeframe signal analysis for various horizons. The analysis suggests a current breakdown that, if sustained, could lead to lower levels, noting elevated downside risk.
Cookson Peirce & Co. Inc. Has $2.50 Million Stake in iRhythm Technologies $IRTC
Cookson Peirce & Co. Inc. significantly increased its stake in iRhythm Technologies (NASDAQ:IRTC) by 105.4% in the third quarter, now holding 14,524 shares valued at approximately $2.50 million. The company's stock has a "Moderate Buy" consensus rating from analysts with an average price target of $219.23, while trading near $148.41. Insider selling also occurred in December, with corporate insiders now owning 1.10% of the stock.
iRhythm Technologies (IRTC) to Release Quarterly Earnings on Thursday
iRhythm Technologies (NASDAQ:IRTC) is scheduled to release its Q4 2025 earnings after market close on Thursday, February 19th, with analysts forecasting EPS of $0.02 and revenue of $202.606 million. The company currently holds a "Moderate Buy" consensus rating with an average target price of $219.23, though insider selling of shares occurred in December. iRhythm specializes in wearable cardiac monitoring devices like the Zio® patch.
iRhythm Reorganization Raises Questions On Valuation And Shareholder Position
iRhythm Technologies, Inc. has undergone a holding company reorganization, with iRhythm Holdings, Inc. becoming the new public entity for shareholders. This change affects NasdaqGS:IRTC stock and prompts investors to consider implications for voting rights, reporting, and trading. The article advises shareholders to review how their positions map to the new entity and highlights a valuation concern, with shares trading significantly above estimated fair value and recent insider selling.
iRhythm Reorganization Raises Questions On Valuation And Shareholder Position
iRhythm Technologies, Inc. has undergone a voluntary reorganization, deregistering its common stock and establishing iRhythm Holdings, Inc. as the new public entity. This change affects shareholders of NasdaqGS:IRTC, prompting questions about voting rights, reporting, and future trading of the stock. While largely administrative, the market is evaluating the new entity against analyst targets and fair value models, especially given recent insider selling and a "stretched" valuation.
Bessemer Group Inc. Sells 134,961 Shares of iRhythm Technologies $IRTC
Bessemer Group Inc. reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 23.7% in the third quarter, selling 134,961 shares and now owning 434,235 shares valued at approximately $74.7 million. Despite the sale, iRhythm Technologies holds a "Moderate Buy" consensus rating from analysts with a target price of $219.23, following multiple price target increases by various brokers. The stock recently opened at $146.75, showing a 3.7% decrease, and has a market capitalization of $4.73 billion.
iRhythm Holdings to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
iRhythm Holdings, Inc. will release its financial results for the fourth quarter and full year 2025 after the market closes on Thursday, February 19, 2026. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Interested parties can access the webcast on the investor relations section of iRhythm's website.
2 Healthcare Stocks with Promising Prospects and 1 We Brush Off
This article evaluates three healthcare stocks, recommending two for potential market-beating returns and advising against one. Organon (OGN) is suggested to be avoided due to declining revenue, less profitable sales, and increased capital intensity. iRhythm Technologies (IRTC) and Alignment Healthcare (ALHC) are highlighted as promising due to strong revenue growth, improved operating margins, and positive free cash flow, respectively.
iRhythm Technologies (NASDAQ:IRTC) Sees Significant Growth in Short Interest
iRhythm Technologies (NASDAQ:IRTC) experienced a notable 19.6% increase in short interest as of January 15th, reaching over 2.75 million shares. This surge in short positions suggests growing bearish sentiment, despite mixed analyst ratings with a consensus of "Moderate Buy" and an average target price of $219.23. Insider selling also occurred in December, with two executives reducing their holdings, while several institutional investors increased their stakes in the company during the fourth quarter.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hologic (HOLX) and Irhythm Technologies (IRTC)
This article discusses analyst sentiments for Hologic (HOLX) and Irhythm Technologies (IRTC). While Hologic received a "Hold" rating from William Blair and TipRanks - OpenAI, Irhythm Technologies was maintained as a "Buy" by William Blair. The reported average price targets suggest a moderate upside for Hologic and a stronger potential for Irhythm Technologies.
HALPER SADEH LLC ENCOURAGES IRHYTHM TECHNOLOGIES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by certain officers and directors of iRhythm Technologies, Inc. Long-term shareholders of iRhythm are encouraged to contact the firm to discuss their legal rights and options, including corporate governance reforms and financial incentives. This action aims to enhance shareholder value by promoting transparency and accountability within the company.
iRhythm Technologies Achieves Profitability Milestone and Sets Ambitious 2026 Targets
iRhythm Technologies closed its 2025 fiscal year with record sales and its first-ever positive free cash flow, marking a significant profitability milestone. The company is projecting a strong 2026 with an adjusted EBITDA margin target of 11.5% to 12.5% and revenue forecasts between $870 million and $880 million, driven by expansion into primary care markets and the integration of AI. iRhythm plans to leverage its Zio monitoring systems and expand into adjacent clinical areas like obstructive sleep apnea, building on its extensive clinical data validating its technology.
Cardiac Event Monitor Market Booming with Rapid Growth Through 2033 | iRhythm Technologies, Preventice Solutions, Medicomp
The Cardiac Event Monitor Market is projected to grow from USD 4.95 billion in 2025 to USD 7.39 billion by 2032, with a CAGR of 5.9%. A new report from Coherent Market Insights offers an in-depth analysis of the market, including segmentation by type, application, patient group, technology, and end-user, along with profiles of key companies like Medtronic and Abbott. The study aims to provide strategic insights and actionable intelligence for decision-makers navigating this evolving market.
Federated Hermes Inc. Has $12.11 Million Stock Position in iRhythm Technologies $IRTC
Federated Hermes Inc. significantly increased its stake in iRhythm Technologies by 45.4% in the Q3, now holding 70,401 shares valued at $12.11 million. Despite the company's unprofitability, analysts maintain a "Moderate Buy" rating with an average target of $219.23, while insiders sold approximately $3.08 million in stock during the last quarter. iRhythm Technologies exceeded Q3 expectations with $192.9 million in revenue, a 30.8% year-over-year increase, and reported an EPS of $(0.06).
Lisanti Capital Growth LLC Makes New Investment in iRhythm Technologies $IRTC
Lisanti Capital Growth LLC has made a new investment in iRhythm Technologies (NASDAQ:IRTC), purchasing 16,830 shares valued at approximately $2.895 million in the third quarter. iRhythm Technologies reported strong Q3 results, beating EPS estimates and showing significant year-over-year revenue growth, despite maintaining negative net margins and return on equity. The stock is currently trading below analysts' average target price of $219.23, with a "Moderate Buy" consensus rating, even as several insiders have sold shares recently.
Y Intercept Hong Kong Ltd Sells 22,037 Shares of iRhythm Technologies $IRTC
Y Intercept Hong Kong Ltd significantly reduced its stake in iRhythm Technologies ($IRTC), selling 22,037 shares and decreasing its holdings by 72.5% in the third quarter. This move comes as other institutional investors have also adjusted their positions, and company insiders, including CEO Quentin S. Blackford, have sold shares totaling over $3 million in the last 90 days. Despite these sales, analysts generally maintain a "Moderate Buy" rating for iRhythm Technologies, with an average target price of $219.23.
Here is Why Hedge Funds Are Appreciating iRhythm Holdings (IRTC)
Hedge funds are increasingly interested in iRhythm Holdings (IRTC), a digital healthcare company specializing in cardiac arrhythmia diagnostics. Recent analyst upgrades from Morgan Stanley and Evercore ISI have set price targets indicating a significant upside, spurred by the company's strong preliminary Q4 results and robust 2026 guidance. iRhythm's innovative Zio biosensor technology and integration of AI-based data analytics are key factors driving this positive sentiment.
Here is Why Hedge Funds Are Appreciating iRhythm Holdings (IRTC)
Hedge funds are showing appreciation for iRhythm Holdings (IRTC) due to strong financial performance and positive analyst outlooks. Morgan Stanley reiterated an Overweight rating with a $205 price target, while Evercore ISI upgraded its rating to Outperform with a $210 target, both citing outperforming preliminary Q4 revenues and promising 2026 guidance. iRhythm Holdings specializes in device-based Zio biosensor technology for cardiac arrhythmia diagnosis, incorporating AI-based data analytics.
HALPER SADEH LLC ENCOURAGES IRHYTHM TECHNOLOGIES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of iRhythm stock to contact them to discuss potential corporate governance reforms, the return of funds to the company, or other relief. Shareholder involvement is emphasized as a way to improve company policies and enhance shareholder value.
Did iRhythm's (IRTC) Upgraded 2025–2026 Revenue Outlook Just Shift Its Investment Narrative?
iRhythm Technologies (IRTC) recently raised its 2025 revenue guidance and provided new 2026 guidance of $870-880 million, signifying strong demand for its cardiac monitoring services. This upgraded outlook reinforces the growth narrative for iRhythm but also elevates expectations for margin improvement. While the stock's premium valuation and lack of profitability present risks, varying fair value estimates highlight different investor perspectives.
Did iRhythm's (IRTC) Upgraded 2025–2026 Revenue Outlook Just Shift Its Investment Narrative?
iRhythm Technologies (IRTC) has raised its 2025 revenue guidance and provided a strong 2026 outlook of US$870-US$880 million, indicating significant year-over-year growth due to high demand for its cardiac monitoring services. This upgraded forecast reinforces the argument for long-term adoption of ambulatory cardiac monitoring as a key investment driver, though the company still faces challenges related to profitability, valuation risk, and execution. The differing fair value estimates among investors highlight the contrasting views on iRhythm's future prospects.
iRhythm Technologies (NASDAQ:IRTC) Given Average Recommendation of "Moderate Buy" by Analysts
iRhythm Technologies (NASDAQ:IRTC) has received an average recommendation of "Moderate Buy" from fifteen analysts, with an average 12-month price target of $219.23. Despite beating revenue and EPS estimates in its latest quarter, the company remains unprofitable, and insiders have been selling shares. Several institutional investors have recently increased their holdings in the company.
How (IRTC) Movements Inform Risk Allocation Models
This article analyzes Irhythm Technologies Inc. (NASDAQ: IRTC), highlighting divergent sentiment across different time horizons, suggesting choppy market conditions. It provides AI-generated institutional trading strategies including long, breakout, and short positions, along with multi-timeframe signal analysis indicating support and resistance levels. The report also mentions elevated downside risk due to a lack of long-term support signals.
iRhythm Technologies $IRTC Shares Sold by Stephens Investment Management Group LLC
Stephens Investment Management Group LLC reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 6.0% in the third quarter, selling 32,958 shares, though it remains a significant holding. Despite this sale, analysts maintain a "Moderate Buy" consensus target price of $219.23 for IRTC. The company exceeded Q3 EPS and revenue estimates, however, it still operates with a negative net margin and return on equity.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) regarding potential breaches of fiduciary duties by its officers and directors. A federal lawsuit alleges that insiders misrepresented the Zio AT monitor's capabilities and market penetration, leading to inflated stock prices. The firm encourages investors who bought IRTC prior to November 5, 2021, to contact them to discuss their legal rights.
Patient Monitoring Stocks Q3 Earnings: iRhythm (NASDAQ:IRTC) Best of the Bunch
The article reviews Q3 earnings for patient monitoring stocks, highlighting iRhythm (NASDAQ:IRTC) as the top performer with a significant revenue beat and strong growth. It also examines the performance of Insulet (NASDAQ:PODD), ResMed (NYSE:RMD), Masimo (NASDAQ:MASI), and DexCom (NASDAQ:DXCM), discussing key financial metrics and market reactions. The industry faces both growth opportunities due to aging populations and chronic diseases, and challenges from R&D costs and regulatory hurdles.
Halper Sadeh LLC Encourages iRhythm Technologies, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether iRhythm Technologies, Inc. (NASDAQ: IRTC) officers and directors breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential corporate governance reforms, recovery of funds, financial incentives, or other relief. Shareholder participation is highlighted as important for improving company oversight and enhancing shareholder value.
Halper Sadeh LLC Encourages iRhythm Technologies, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential rights, including corporate governance reforms or financial incentives. Shareholder involvement is emphasized as a way to improve company transparency and enhance shareholder value.
SG Americas Securities LLC Trims Stock Position in iRhythm Technologies $IRTC
SG Americas Securities LLC reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 51.2% in the third quarter of 2025, selling over 14,000 shares. Despite this institutional selling, iRhythm Technologies has a positive outlook with improved revenue guidance for fiscal year 2026, record unit volume, and first-time free cash flow positivity. Analysts maintain a "Moderate Buy" rating with an average price target of $219.23, although significant insider selling has occurred.
iRhythm Technologies (IRTC) Is Down 8.6% After Surpassing 2025 Guidance And Turning Free Cash Flow Positive
iRhythm Technologies (IRTC) reported exceeding its 2025 revenue guidance and projected high-teens growth for 2026, alongside achieving its first quarter of positive free cash flow. Despite these positive updates and expansion into new areas like obstructive sleep apnea, the stock saw an 8.6% decline. The article emphasizes that while current data supports growth, risks related to competition, reimbursement, and regulatory scrutiny remain significant.
iRhythm Technologies: Best in Business 2025
iRhythm Technologies has been recognized as "Best in Business 2025" in the Medical Technology (MedTech) category by Modern Healthcare. The article highlights this specific award for the company.
iRhythm Technologies (NASDAQ:IRTC) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC has reiterated a "buy" rating for iRhythm Technologies (NASDAQ:IRTC) with a $244 price target, suggesting a 41.8% upside. The company exceeded EPS and revenue expectations in its last quarter, though it remains unprofitable with projected negative EPS for the fiscal year. Despite recent insider share sales, institutional investors have shown strong interest by materially increasing their positions.
iRhythm Technologies Inc Anticipate Fy25 Revenue To Exceed High End Of Previously Stated Guidance Range Of $740 Million Provided In October 2025
iRhythm Technologies Inc. is forecasting its fiscal year 2025 revenue to surpass the upper limit of its previously announced guidance range of $740 million. This news, reported by Refinitiv, indicates a positive financial outlook for the company. The article, however, consists only of the headline.
